<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782221</url>
  </required_header>
  <id_info>
    <org_study_id>GH02</org_study_id>
    <nct_id>NCT02782221</nct_id>
  </id_info>
  <brief_title>Lipolytic Effects of GH in Human Subjects in Vivo</brief_title>
  <official_title>Lipolytic Effects of GH in Human Subjects in Vivo: Molecular Mechanisms and Temporal Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing
      effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism,
      and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore
      hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent
      signaling pathways.

      In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose
      tissue biopsies taken after GH exposure and GH blocking, respectively.

      Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in
      long-sight have great importance for the understanding of growth disorders from overweight
      and type 2 diabetes to malnutrition and eating disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipolytic activity measured as area under the curve (AUC) for FFA (blood sample).</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate metabolism as measured by indirect calorimetry</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH signaling proteins in adipose tissue measured by western blotting</measure>
    <time_frame>1,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular lipolytic activity measured by an ATGL assay</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH signaling gene targets in adipose tissue measured by qPCR</measure>
    <time_frame>1,5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Metabolic Diseases</condition>
  <condition>Growth Hormone Treatment</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are receiving growth hormone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are receiving pegvisomant to block the action of growth hormone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg</description>
    <arm_group_label>Growth hormone</arm_group_label>
    <other_name>Genotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegisomant</intervention_name>
    <description>One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy males

          -  no medication

          -  BMI 28-35

        Exclusion Criteria:

          -  known diseases

          -  regular medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Otto L Jørgensen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astrid J Hjelholt, MD</last_name>
    <phone>+4524800664</phone>
    <email>ajh@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Otto L Jørgensen, Professor</last_name>
    <phone>+4520727383</phone>
    <email>joj@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid J Hjelholt, MD</last_name>
      <phone>+4524800664</phone>
      <email>ajh@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Nielsen TS, Jessen N, Jørgensen JO, Møller N, Lund S. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol. 2014 Jun;52(3):R199-222. doi: 10.1530/JME-13-0277. Epub 2014 Feb 27. Review.</citation>
    <PMID>24577718</PMID>
  </reference>
  <reference>
    <citation>Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152-77. doi: 10.1210/er.2008-0027. Epub 2009 Feb 24. Review.</citation>
    <PMID>19240267</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lipolysis</keyword>
  <keyword>ATGL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

